Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 24, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With

Baris Turkbey1, Esther Mena, Liza Lindenberg

  • 1From the *Molecular Imaging Program, National Cancer Institute, Bethesda; †Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick, MD; ‡Institute of Diagnostic Radiology, Department of Medical Area, University of Udine, Udine, Italy; §Office of the Clinical Director/Center for Cancer Research/National Cancer Institute, Bethesda; ∥Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick; ¶Office of the Pharmaceutical Quality, FDA/CDER, Silver Spring; **Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore; ††Laboratory of Pathology, National Cancer Institute, Bethesda; ‡‡Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville; §§Center for Interventional Oncology, National Cancer Institute and Clinical Center, and Radiology Imaging Sciences, National Institutes of Health, Bethesda; and ∥∥Urologic Oncology Branch, National Cancer Institute, Bethesda, MD.

Clinical Nuclear Medicine
|August 15, 2017
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.

Abdominal radiology (New York)·2024
Same author

Non-Invasive Tumor Grade Evaluation in Von Hippel-Lindau-Associated Clear Cell Renal Cell Carcinoma: A Magnetic Resonance Imaging-Based Study.

Journal of magnetic resonance imaging : JMRI·2024
Same author

Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study.

Academic radiology·2024
Same author

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

Cancer cell·2023
Same author

Quality of T2-weighted MRI re-acquisition versus deep learning GAN image reconstruction: A multi-reader study.

European journal of radiology·2023
Same author

Invited Commentary: Advanced Anatomic and Molecular Imaging in Recurrent Prostate Cancer.

Radiographics : a review publication of the Radiological Society of North America, Inc·2023
Summary

F-DCFBC PET/CT detects most index prostate cancers, potentially aiding staging. However, combining F-DCFBC PET/CT with multiparametric MRI (mpMRI) is crucial for high-sensitivity prostate cancer detection.

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Prostate cancer detection relies on accurate imaging for staging and treatment planning.
  • Multiparametric MRI (mpMRI) is a key tool, but novel PET agents are emerging for enhanced visualization.

Purpose of the Study:

  • To evaluate the efficacy of F-DCFBC PET/CT in detecting localized prostate cancer.
  • To compare F-DCFBC PET/CT performance against mpMRI and histopathology.
  • To assess F-DCFBC uptake in cancerous lesions versus benign tissue.

Main Methods:

  • Prospective study of 13 patients with localized prostate cancer undergoing mpMRI and F-DCFBC PET/CT.
  • Lesion biopsy or radical prostatectomy for histopathological correlation.
  • Blinded, separate evaluation of mpMRI and F-DCFBC PET/CT, followed by image fusion and correlation with histology.

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.7K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.5K

Related Experiment Videos

Last Updated: Feb 24, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.7K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.5K

Main Results:

  • F-DCFBC PET/CT sensitivity was 36% for all tumors and 61.5% for index lesions.
  • mpMRI demonstrated higher sensitivity (96% for all tumors, 92% for index lesions).
  • F-DCFBC showed significantly higher SUVmax in primary prostate cancer compared to benign or normal tissue (P = 0.0033).

Conclusions:

  • F-DCFBC PET/CT can detect the majority of index prostate cancers and may serve as a prognostic indicator.
  • Combining F-DCFBC PET/CT with mpMRI is recommended for optimal sensitivity in prostate cancer detection.